|10th November 2020||Fuad El Hibri||19,391||Open or private sale||$88.21||$1,710,480.11|
|10th November 2020||Fuad El Hibri||19,391||Exercise of derivative||$26.45||$512,891.95|
|9th November 2020||Fuad El Hibri||20,000||Open or private sale||$95.26||$1,905,200.00|
|9th November 2020||Fuad El Hibri||20,000||Exercise of derivative||$26.45||$529,000.00|
|6th November 2020||Kevin C Tang||34,044||Open or private purchase||$20.63||$702,327.72|
|6th November 2020||Kevin C Tang||29,682||Open or private purchase||$22.33||$662,799.06|
|6th November 2020||Kevin C Tang||2,650||Open or private purchase||$23.87||$63,255.50|
|6th November 2020||Kevin C Tang||107,901||Open or private purchase||$23.48||$2,533,515.48|
|5th November 2020||Kevin C Tang||8,482||Open or private purchase||$20.94||$177,613.08|
|5th November 2020||Kevin C Tang||137,241||Open or private purchase||$20.78||$2,851,867.98|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Aptevo Therapeutics, Inc. was founded on February 22, 2016 and is headquartered in Seattle, WA. Its pipeline includes APVO210, APVO436, ROR1 Candidate, and ALG.APV-527.